Skip to main content

Advertisement

Table 1 Baseline patient characteristics of each included article

From: Risk of febrile neutropenia among patients with multiple myeloma or lymphoma who undergo inpatient versus outpatient autologous stem cell transplantation: a systematic review and meta-analysis

References Group No. Sex (M/ F) Median age (years, range) HCT-CI ECOG-PS/ KPS* Diseases Donor source Median CD 34 + (× 106 cells/kg, range) Study period Type Quality assessment
Morabito 2002 [23] OP 29 19/10 55.3 NR NR MM: 29 PBSC 5.3 1998–2001 R Selection: 3 Comparability: 2 Outcome: 2
IP 27 18/9 49.6 NR NR MM: 27 PBSC 6.4
Ferna’ndez-Avilés 2006 [24] OP 50 31/19 47 (20–65) NR 0: 25, 1: 18, 2: 7 MM:13, Lym: 28, ALL: 4, AML: 1, CML: 2, CLL: 2 PBSC except 1 case was mixed source 3.2 (1.8–21) 2000–2005 R Selection: 3 Comparability: 2 Outcome: 2
IP 50 27/23 50 (20–68) NR 0: 23, 1: 18, 2: 9 MM:13, Lym:28, ALL 3, AML: 2, CML: 2, CLL: 2 PBSC except 1 case was mixed source 2.7 (0.9–15)
Martino 2015 [25] OP 25 18/7 59 (42–65) NR NR MM: 25 NR 5 (2.1–5.9) NR P Selection: 4 Comparability: 2 Outcome: 2
IP 33 20/13 62 (43–67) NR NR MM 33 NR 4.9 (2.1–5.8)
Graff 2015 [26] OP 95 63/32 58 (20–76) 0–2: 57 ≥3: 38 ≤80: 6, 90: 49, 100: 40 MM: 63, Lym: 32 NR 4.4 (1.9–12.9) 2009–2012 R Selection: 3 Comparability: 2 Outcome: 3
IP 135 86/49 59 (21–76) 0–2: 64 ≥3: 71 ≤80: 36, 90: 72, 100: 27 MM: 88, Lym: 47 NR 4.6 (1.9–16.5)
Paul 2015 [27] OP 82 51/31 59 (28–71) 0–1: 82 NR MM: 82 NR NR 2003–2010 R Selection: 3 Comparability: 2 Outcome: 2
IP 219 128/91 60 (29–75) 0–1: 219 NR MM: 219 NR NR
Reid 2016 [28] OP 58 38/20 58 (17–72) 0–2: 46 ≥3: 12 NR Lym: 58 PBSC 4.6 (2–16.8) 2011–2014 R Selection: 4 Comparability: 2 Outcome: 2
IP 49 30/19 59 (16–74) 0–2: 37 ≥ 3: 12 NR Lym: 49 PBSC 4.2 (2–18.9)
Abid 2017 [29] OP 10 6/4 56 (39–62) 0–2: 10 0: 6, 1: 4, 2: 0 MM: 10 PBSC 9.2 (2.8–18.9) 2011–2015 R Selection: 2 Comparability: 2 Outcome: 2
IP 11 6/5 58 (45–64) 0–2: 9, ≥3: 2 0: 5, 1: 4, 2: 2 MM: 11 PBSC 8.5 (2.5–17.8)
Lisenko 2017 [30] OP 14 9/5 NR NR 0–1: 14 MM: 14 PBSC 9.7 (7.4–24.8) 2012–2016 R Selection: 3 Comparability: 2 Outcome: 2
IP 7 6/1 NR NR 0–1: 7 MM: 7 PBSC 13.7 (9.1–23)
Shah 2017 [31] OP 377 234/143 58 (34–78) < 3: 207 ≥ 3: 170 90* MM: 377 NR NR 2008–2012 R Selection: 3 Comparability: 2 Outcome: 2
IP 669 369/300 62 (31–82) < 3: 301 ≥ 3: 368 90* MM: 669 NR NR
  1. Abbreviations: ALL Acute lymphoblastic leukemia, AML Acute myeloid leukemia, CLL Chronic lymphocytic leukemia, CML Chronic myeloid leukemia, ECOG-PS Eastern Cooperative Oncology Group-Performance status, F Female, HCT-CI Hematopoietic Cell Transplantation-Comorbidity Index, IP Inpatient, KPS Kanofsky performance status, Lym Lymphoma, M Male, MM Multiple myeloma, NR Not reported, OP Outpatient, P Prospective cohort, PBSC Peripheral blood stem cell, R Retrospective cohort